Issued: London, UK

For media and investors only

ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024

  • Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato (dolutegravir/lamivudine) or Biktarvy (bictegravir/emtricitabine/ tenofovir alafenamide)
  • Additional key abstracts from ViiV Healthcare’s industry-leading, long-acting pipeline and portfolio include data introducing a third-generation integrase strand transfer inhibitor (INSTI) with potential for ultra long-acting applications; pregnancy data for Apretude (cabotegravir long-acting injectable) for PrEP; and real-world evidence for long-acting treatment regimen Cabenuva (cabotegravir + rilpivirine long-acting)

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will be presenting the largest head-to-head, randomised clinical trial (RCT) of the 2-drug regimen Dovato (dolutegravir/lamivudine [DTG/3TC]) compared against the 3-drug regimen, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]) at the 25th International AIDS Conference in Munich, Germany (22 – 26 July). The presentation is one of 25 abstracts evaluating the company’s portfolio of marketed HIV treatment and prevention options alongside its next-generation pipeline assets.

Harmony P. Garges, M.D., Chief Medical Officer at ViiV Healthcare, said: The exciting findings we’ll be presenting at AIDS 2024 continue to underscore our position as industry leaders in the development of long-acting and 2-drug regimens and our pioneering approaches to both HIV treatment and prevention. People living with HIV continue to tell us they want more treatment options to allow for more personal choice to address needs beyond viral suppression. The breadth of the data we’re announcing, including the head-to-head study between Dovato and Biktarvy, helps individuals better understand those options. We’re proud to be at the forefront of innovative science, driving advancements that have and will continue to transform the future of HIV care and contribute to ending the epidemic.”

Key abstracts to be presented at AIDS 2024 by ViiV Healthcare and its study partners will include:

Head-to-head study comparing ViiV Healthcare’s oral 2-drug regimen against a commonly prescribed oral 3-drug regimen: The FSG-sponsored PASO-DOBLE head-to-head RCT of the 2-drug regimen Dovato (DTG/3TC) compared with the 3-drug regimen Biktarvy (BIC/FTC/TAF) will be presented as a late breaker abstract. The non-inferiority study assessed virologically suppressed adults on an established treatment regimen and who could benefit from treatment optimisation, who were randomised to switch to treatment with DTG/3TC or BIC/FTC/TAF. Researchers will share 48-week findings on treatment efficacy and safety, as well as changes in weight experienced by participants while taking either regimen.1

Additional findings for DTG/3TC will include the DYAD study, presenting 48-week findings among virologically suppressed participants with no prior virologic failure who either switched to DTG/3TC or remained on BIC/FTC/TAF;2 and 96-week findings from the SOUND study, which followed virologically suppressed participants with unknown resistance history who switched from BIC/FTC/TAF to DTG/3TC.3

Pregnancy data from the HPTN 084 open label extension study for Apretude: New findings will be presented from the HPTN 084 trial that assess the impact of cabotegravir long-acting (LA) for PrEP exposure during pregnancy.4,5 The study focuses on maternal, pregnancy, and infant safety outcomes among participants who became pregnant during the open label extension of HPTN 084 and continued with injections of cabotegravir LA for PrEP.

New pipeline data from ViiV Healthcare’s third generation INSTI: Researchers will share phase I findings from the first-time-in-human study of VH184, a third-generation integrase inhibitor (INSTI), along with analysis showing potent activity in vitro against multiple INSTI resistant mutations.6 This is the first data presentation of the company’s next INSTI as a part of its ultra long-acting development strategy.

Real-world evidence from long-acting treatment regimen: Findings from several real-world studies of the complete long-acting HIV treatment regimen cabotegravir + rilpivirine long-acting (CAB+RPV LA) will be presented, including the perspectives of people living with HIV 12 months after switching their treatment regimen to CAB+RPV LA from the BEYOND study;7,8 effectiveness, participant adherence to injections, and patient reported outcomes from the German cohort of the CARLOS study;9 and utilisation and effectiveness of CAB+RPV LA among virologically suppressed, treatment-experienced individuals from the COMBINE-2 study.10

Here is a list of ViiV Healthcare-sponsored or supported studies to be presented at AIDS 2024:

Title First Author Presentation Number Presentation

Dolutegravir/3TC 

Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASODOBLE (GeSIDA 11720) randomized clinical trial

  P. Ryan

OAB3606LB 

Oral

Session date: Friday, 26 July

Session time: 12:00-13:00 CEST

PAIRED - Patient reported experiences and perceived benefit of treatment with dolutegravir/lamivudine - qualitative interviews: diverse group of people with HIV-1 (PWH) reflect on life and health

J. Slim

THPEB094

Poster

Date of presentation: Thursday, 25 July

Time of presentation: 12:00-13:00 CEST

Real-world effectiveness and tolerability of the 2-drug regimen dolutegravir and lamivudine (DTG/3TC) in people living with HIV: a systematic literature review and meta-analysis from clinical practice

J. Fraysse

 

TUPEB101

Poster

Date of presentation: Tuesday, 23 July

Time of presentation: 12:00-13:00 CEST

Effectiveness and durability of dolutegravir/lamivudine in older people with HIV from the Veterans Aging Cohort Study (VACS)

L. Yan

WEPEB111

Poster

Date of presentation: Wednesday, 24 July

Time of presentation: 12:00-13:00 CEST

Switch to dolutegravir/lamivudine (DTG/3TC) in people living with HIV-1 suppressed on bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF): 96-week final analysis from the SOUND study 

J. Slim

THPEB092

Poster

Date of presentation: Thursday, 25 July

Time of presentation: 12:00-13:00 CEST

Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide - 48-week results from the DYAD study

C. Rolle

THPEB089

Poster

Date of presentation: Thursday, 25 July

Time of presentation: 12:00-13:00 CEST

Dolutegravir

Viral suppression, viral failure and safety outcomes in children and adolescents on dolutegravir (DTG) in Europe and Thailand

K. Scott

OAB3803

Oral

Session date: Friday, 26 July

Session time: 13:30-14:30 CEST

Changes in body mass index in children and adolescents in Europe and Thailand before and after starting dolutegravir and compared to protease inhibitors using propensity scoring analysis

S. Crichton

 

TUPEB086

Poster

Date of presentation: Tuesday, 23 July

Time of presentation: 12:00-13:00 CEST

Prenatal dolutegravir-based regimen use, and pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry

V. Vannappagari

TUPEB128

Poster

Date of presentation: Tuesday, 23 July

Time of presentation: 12:00-13:00 CEST

Effectiveness and durability of dolutegravir/ rilpivirine in older people with HIV from the Veterans Aging Cohort Study (VACS)

L. Yan

THPEB090

Poster

Date of presentation: Thursday, 25 July

Time of presentation: 12:00-13:00 CEST

Cabotegravir for treatment

Subcutaneous injections of cabotegravir + rilpivirine in virally suppressed adults with HIV-1: a substudy of the phase 3 FLAIR study

R. D’Amico

OAB2604

Oral

Session date: Thursday, 25 July 2024

Session time: 15:00-16:00 CEST

Clinical outcomes at month 12 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND)

S. Schneider

THPEB099

Poster

Date of presentation: Thursday, 25 July

Time of presentation: 12:00-13:00 CEST

Perspectives of people with HIV (PWH) 12 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)

W. Valenti

 

TUPEB116

Poster

Date of presentation: Tuesday, 23 July

Time of presentation: 12:00-13:00 CEST

12-Month outcomes of cabotegravir plus rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence to injections, and patient-reported outcomes from people with HIV-1 in the German CARLOS cohort

C. Jonsson-Oldenbüttel

 

TBUPEB095

Poster

Date of presentation: Tuesday, 23 July

Time of presentation: 12:00-13:00 CEST

Increased screening for sexually transmitted infections and HIV surrogate marker testing among long-acting injectable versus daily oral antiretroviral therapy users in the OPERA® cohort

P. C. Lackey

WEPEC319

Poster

Date of presentation: Wednesday, 24 July

Time of presentation: 12:00-13:00 CEST

Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine in virologically suppressed treatment experienced individuals in Europe: data from COMBINE-2 cohort study

A. Pozniak

TUPEC278

Poster

Date of presentation: Tuesday, 23 July

Time of presentation: 12:00-13:00 CEST

Re-thinking ‘community’ in the implementation of long-acting injectable cabotegravir and rilpivirine: qualitative findings from the ILANA study

R. Hayes

TUPEE529

Poster

Date of presentation: Tuesday, 23 July

Time of presentation: 12:00-13:00 CEST

Adherence through the prism of long-acting injectable therapy: qualitative findings from the ILANA implementation study

S. Paparini

TUPED306

Poster

Date of presentation: Tuesday, 23 July

Time of presentation: 12:00-13:00 CEST

“Closer to a cure:” mixed-methods analysis of reasons for switching to cabotegravir + rilpivirine

S. Paparini

WEPEE551

Poster

Date of presentation: Wednesday, 24 July

Time of presentation: 12:00-13:00 CEST

Cabotegravir for PrEP

“The simplest way to go:” A mixed methods analysis of why women who inject drugs selected long-acting injectable cabotegravir instead of daily oral PrEP

A. M. Roth

OAD07

Oral

Session date: Tuesday, 23 July

Session time: 17:05-17:13 CEST

Knowledge, awareness, feasibility, and acceptability of long-acting cabotegravir for HIV prevention: results from the SEARCH Dynamic Choice HIV prevention trial

E. Kakande

OAE12

Oral

Session date: Wednesday, 24 July

Session time:10:41-10:49 CEST

Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) in the US currently using daily-oral PrEP

J. L. Glick

WEPEC269

Poster

Date of presentation: Wednesday, 24 July

Time of presentation: 12:00-13:00 CEST

HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons with high likelihood of HIV in the United States: recent results from the Transgender Women’s Internet Survey and Testing (TWIST)

D. I. Yaras

THPEC186

Poster

Date of presentation: Thursday, 25 July

Time of presentation: 12:00-13:00 CEST

Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort

E. E. Cooney

THPED410

Poster

Date of presentation: Thursday, 25 July

Time of presentation: 12:00-13:00 CEST

Influencers and decision-making factors for choosing injectable PrEP among men who have sex with men and transgender men in the United States

D. Dandachi

THPEE504

Poster

Date of presentation: Thursday, 25 July

STime of presentation: 12:00-13:00 CEST

Need for increased HIV testing prior to and during pre-exposure prophylaxis with cabotegravir long-acting injections in routine clinical care in the United States

R. K. Hsu

WEPEB046

Poster

Date of presentation: Wednesday, 24 July

Time of presentation: 12:00-13:00 CEST

Pre-exposure prophylaxis (PrEP) product choice of participants in HPTN 083

M. E. Clement

TUPEC184

Poster

Date of presentation: Tuesday, 23 July

Time of presentation: 12:00-13:00 CEST

“Everyone should have access to it”: Perspectives on PrEP product choice and implementation from MSM and TGW in an injectable PrEP trial

C. Psaros

WEPEC206

Poster

Date of presentation: Wednesday, 24 July

Time of presentation: 12:00-13:00 CEST

Pipeline

Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile

L. Rogg

OAB26

Oral

Session date: Thursday, 25 July

Session time: 15:00-16:00 CEST

Preclinical assessments of a cabotegravir prodrug predicting human dosing durations of >6 months

M. Baker

WEPEA028

Poster

Date of presentation: Wednesday, 24 July

Time of presentation: 12:00-13:00 CEST

Pre-clinical profiles of HIV-1 capsid inhibitors VH4004280 (VH-280) and VH4011499 (VH-499)

C. Wang

WEPEA027

Poster

Date of presentation: Wednesday, 24 July

Time of presentation: 12:00-13:00 CEST

Clinical pharmacokinetics and safety of orally administered VH4004280 (VH-280), a novel HIV-1 capsid inhibitor, in healthy volunteers

R. Griesel

THPEB093

Poster

Date of presentation: Thursday, 25 July

Time of presentation: 12:00-13:00 CEST

Clinical pharmacokinetics and safety of orally administered VH4011499 (VH-499), a novel HIV-1 capsid inhibitor, in healthy volunteers

N. Thakkar

WEPEB105

Poster

Date of presentation: Wednesday, 24 July

Time of presentation: 12:00-13:00 CEST

Above Brand

Detailed modelling of viremia exposure does not independently predict cardiovascular disease in people with HIV

O. Elvstam

OAB34

Oral

Session date: Friday, 26 July 2024

Session time: 10:30-11:30 CEST

About Dovato

Dovato is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Dovato.

Please consult the full Summary of Product Characteristics for all the safety information: Dovato 50 mg/300 mg film-coated tablets.

About Vocabria

Vocabria (cabotegravir) injection is indicated - in combination with rilpivirine injection - for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class.

Vocabria tablets are indicated - in combination with rilpivirine tablets - for the short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:

  • oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting Vocabria injection plus long acting rilpivirine injection.
  • oral therapy for adults who will miss planned dosing with Vocabria injection plus rilpivirine injection.

Vocabria tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for Edurant tablets should also be consulted for recommended dosing.

Please consult the full Summary of Product Characteristics for all the safety information: Vocabria 400mg/600 mg prolonged-release suspension for injection and Vocabria 30 mg film-coated tablets

About Rekambys

Rekambys is indicated - in combination with cabotegravir injection - for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class.

Rekambys should always be co-administered with a cabotegravir injection. The prescribing information for cabotegravir injection should be consulted for recommended dosing. Rekambys may be initiated with oral lead-in or without (direct to injection).

Please consult the full Summary of Product Characteristics for all the safety information: Rekambys 600mg/900 mg prolonged-release suspension for injection

About Apretude

Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. It should be used in combination with safer sex practices, such as using condoms. Apretude contains the active substance cabotegravir.

Please consult the full Summary of Product Characteristics for all the safety information: Apretude 600 mg prolonged-release suspension for injection

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline and commitment please visit viivhealthcare.com.

About SEIMC-GeSIDA Foundation (FSG)

The SEIMC-GeSIDA Foundation (FSG) was founded by the Spanish Society of Clinical Microbiology and Infectious Diseases as a tool to promote high-quality investigation in the field of HIV infection and other infectious diseases. The Foundation is composed of qualified professionals with experience in the field of clinical trials and multicentre studies. Its streamlined infrastructure facilitates performance of clinical studies and responds to the needs of investigators in terms of methodology/statistical analysis and of logistics and management of trials and other multicentre studies. For more information on the SEIMC-GeSIDA Foundation (FSG), please visit https://fundacionseimcgesida.org/en/quienes-somos/

About GSK   

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q1 Results for 2024.

References

  1.  P. Ryan, et al. Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASODOBLE (GeSIDA 11720) randomized clinical trial. Presented at the 25th International AIDS Conference. July 2024.
  2. C.P. Rolle, et al. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide - 48-week results from the DYAD study. Presented at the 25th International AIDS Conference. July 2024.
  3. J. Slim, et al. Switch to dolutegravir/lamivudine (DTG/3TC) in people living with HIV-1 suppressed on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): 96-week final analysis from the SOUND study. Presented at the 25th International AIDS Conference. July 2024.
  4. S. Delany-Moretlwe, et al. Initial evaluation of CAB-LA Safety during pregnancy in the HPTN 084 open-label extension. Presented at the 25th International AIDS Conference. July 2024.
  5. M. Marzinke, et al. Evaluation of Long-Acting Cabotegravir (CAB-LA) Pharmacokinetics During Pregnancy: A Sub-Study Analysis of the HPTN 084 Open Label Extension. Presented at the 25th International AIDS Conference. July 2024.
  6. L. Rogg, et al. Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile. Presented at the 25th International AIDS Conference. July 2024.
  7. S. Schneider, et al. Clinical outcomes at Month 12 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). Presented at the 25th International AIDS Conference. July 2024.
  8. W. Valenti, et al. Perspectives of people with HIV (PWH) 12 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND). Presented at the 25th International AIDS Conference. July 2024.
  9. CJ. Oldenbüttel, et al. 12-Month outcomes of cabotegravir plus rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence to injections, and patient-reported outcomes from people with HIV-1 in the German CARLOS cohort. Presented at the 25th International AIDS Conference. July 2024.
  10. A. Pozniak, et al. Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine in virologically suppressed treatment experienced individuals in Europe: data from COMBINE-2 cohort study. Presented at the 25th International AIDS Conference. July 2024.